Classic and Novel Sex Hormone Binding Globulin Effects on the Cardiovascular System in Men

Carla Basualto-Alarcón,1,2 Paola Llanos,3 Gerardo García-Rivas,4 Mayarling Francisca Troncoso,5 Daniel Lagos,5 Genaro Barrientos,5 and Manuel Estrada5

1Departamento de Ciencias de la Salud, Universidad de Aysén, Coyhaique 5951537, Chile
2Departamento de Anatomía y Medicina Legal, Facultad de Medicina, Universidad de Chile, Santiago 8389100, Chile
3Institute for Research in Dental Sciences, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
4Tecnológico de Monterrey, Hospital Zambrano Hellion, TecSalud, Centro de Medicina Funcional, San Pedro Garza García, Nuevo León 66278, Mexico
5Programa de Fisiología y Biofísica, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8389100, Chile

Correspondence should be addressed to Manuel Estrada; iestra@med.uchile.cl

Received 12 February 2021; Revised 28 June 2021; Accepted 5 July 2021; Published 21 July 2021

1. Introduction

The incidence of cardiovascular mortality is higher in men than in women [1–3], and gender differences are highly related to circulating plasma levels of sex-steroid hormones [4, 5]. Estrogens have cardioprotective effects in women prior to menopause, but in adult men, the main gender-related steroid hormone is testosterone [6]. A study from the Mayo Clinic (2018) exhaustively reviewed and analyzed the main clinical publications in the last 10 years related to plasma testosterone levels, testosterone administration therapies, and their impact on the cardiovascular system.
Evidence indicates that physiological testosterone levels are beneficial for the male cardiovascular system, while testosterone deficiency is associated with an unfavorable metabolic profile and increased cardiovascular risk [7].

Sex hormone binding globulin (SHBG) transports testosterone within the blood stream and regulates its bioavailability and access to extravascular target tissues [8, 9]. In men, plasma testosterone levels fluctuate throughout life and begin to decrease in middle age and continue to decline with age [4]. Low plasma testosterone levels in men have been associated with the concept of “andropause,” which rapidly has become a worldwide epidemic condition related to an adverse cardiometabolic risk profile [4, 10, 11]. There is substantial clinical evidence indicating that androgen signaling plays a key role for the cardioprotective benefits elicited by physiological testosterone levels in men.

Several cross-sectional and cohort studies have shown that low SHBG levels are associated with an increased risk of developing metabolic diseases [12, 13]. An association has also been described between SHBG actions unrelated to the transport of sex hormones and metabolic disorders. A meta-analysis examining different concentrations of SHBG showed that low levels of SHBG in men are a predictor of metabolic syndrome and type 2 diabetes [14]. Metabolic abnormalities are closely associated with cardiovascular disease [15–17]. Despite previous evidence, a recent cohort study including about 150,000 middle-aged and aged adult men (40–69 years old) concluded that low circulating SHBG levels are associated with diminished mortality in “all-cause” included in this study, particularly those related with cancer and cardiovascular diseases (CVDs). For total and calculated free testosterone, the expected inverse association with SHBG levels was observed only for “all-cause” and cancer mortality and not for CVD deaths [18]. Another cohort study showed, in a group with age ranging from 35 to 80 years, that elevated levels in SHBG were positively associated with increased incidental cardiovascular disease risk in men over 65 years [19]. However, it is still unknown whether changes in the circulating plasma levels of SHBG, the local expression of SHBG and androgen-binding proteins in tissues such as the heart, or the secondary effects of SHBG level fluctuations in free testosterone are responsible for these effects. In this review, we are going to discuss the mechanisms currently proposed for SHBG cardioprotective effects and how the use of circulating SHBG levels can be useful as an early metabolic and cardiovascular biomarker.

2. SHBG Is not Only a Passive Carrier for Sex-Steroids

In men, approximately 70% of circulating plasma testosterone binds with high affinity to circulating SHBG, 20–30% to albumin, and the remaining 1-2% circulates in free form [20]. In women, the majority of plasma estradiol and testosterone are bound to SHBG and other proteins and is not bioavailable; only about 2% of these sex hormones are free to bind to receptors and have an impact on the body [21]. Circulating SHBG modulates the level of free sex-steroid hormones that can enter to diverse target cells [22]. The endocrinological concept known as “free hormone hypothesis” states that the “bioavailable” steroid hormone, i.e., the one that has an effect when bound to its receptor, is the unbound or “free” fraction of steroid hormones [23]. However, recent evidence indicates that circulating SHBG not only is a passive carrier of male sex hormones but also actively regulates testosterone uptake and androgen signaling [24]. Because circulating SHBG binds to sex hormones, the relative plasma levels of this protein can modulate the concentrations of sex-related hormones accessible for use by the body, which has an impact on the processes regulated by the sex hormones [25]. SHBG can also release hormones in specific tissues and cells directly, which can influence both production and effects of sex hormones as well as the expression and function of circulating SHBG. Also, sex hormones bound to circulating SHBG can change the affinity of SHBG to its peripheral receptors. Moreover, intracellular expression of SHBG in testicular proximal tubule cells increases uptake of dihydrotestosterone and prolongs the expression of androgen-responsive genes [26].

One case description of a patient with a homozygous missense mutation in SHBG, which abrogates protein secretion in a 27-year-old man showed low total testosterone but normal free testosterone levels. Despite this, no alterations were seen in sexual development. However, fatigue, muscle weakness, and impaired exercise tolerance were part of the patient’s symptoms. Faced with normal levels of free testosterone, this phenotype suggests that circulating SHBG may affect tissues in a manner dependent or independent of testosterone [27]. Frairia et al. studied tissue distribution of the SHBG membrane receptor either in estrogen/androgen-dependent tissues and proposed that the actions of SHBG in tissues are not strictly sex-steroid-dependent [28]. There is evidence suggesting that circulating SHBG interacts with specific proteins in the plasma membrane and it can be internalized once it is accumulated [29]. In steroidogenic tissues, SHBG can be internalized to activate transduction signaling pathways different and independent of those induced by the classical action mechanism based on intracellular androgen receptors [30]. There is also evidence indicating that circulating SHBG, through LG domains, binds membrane receptors with tyrosine kinase activity and G-protein-coupled receptors [20]. Functional plasma membrane receptors for SHBG have been identified in cardiac tissue [31], and SHBG is expressed in the myocardium [32].

2.1. Circulating SHBG Internalization. Circulating SHBG protein may be internalized through the low-density lipoprotein-related protein 2 receptor also known as megalin receptor in rat yolk cells. Megalin-deficient mice display defects resembling animals treated with androgen receptor antagonists [30]. Megalin is expressed in several tissues including derived cardiac cells [33]. The human megalin promoter gene possessesPPARs-responsive elements, suggesting a metabolic regulation in the protein expression [34]. In fact, megalin expression is reduced in Ren2 rats, a model of metabolic syndrome [35]. Megalin facilitates the uptake of several
ligands, many of which are cataloged as intracrine, including SHBG [36]. These extracellular molecules can act by initiating intracellular signals after internalization. The main intracellular target sites described for intracrine actions include the nucleus and mitochondria. In C2C12, a mouse myoblast cell line, megalin KO, decreases the respiratory and glycolytic capacity [37]. Megalin mediates the retrograde trafficking of TGF-β and angiotensin II to mitochondria through the retrograde early endosome-to-Golgi transport pathway and Rab32 [37], all of this playing a role in mitochondrial physiology. Whether the metabolic effects of SHBG are related to its retrograde transport and if this trafficking is related to mitochondrial modulation in cardiac cells are unknown.

2.2. SHBG as an External Ligand. SHBG activates several signaling pathways depending on a putative membrane receptor coupled to a G-protein [38], increasing the intracellular cAMP levels in COS-1 cells. An increase in cAMP in MCF-7 cells results as a receptor-mediated action of sex-binding protein [39]. Although stimulation of the cAMP pathway has positive effects on cardiac function, long-term activation produces detrimental effects in the myocardium inducing hypertrophy and heart failure [40]. In lymphocytes, incubation with SHBG induces the phosphorylation of ERK and Akt kinases, an effect that is increased by coincubating with estradiol [41]. All these pathways have been implicated as possible targets in metabolic disorders [42–45].

3. Signal Transduction Pathways Involved in SHBG Expression

SHBG is a glycoprotein synthesized and secreted by the liver [46–48] that transports sex-steroids (androgens and estrogens) from steroidogenic organs to their target tissues [6, 20, 24, 49, 50]. The structural organization of SHBG genes is evolutionarily conserved and is expressed in most vertebrates [51, 52]. Additionally, SHBG mRNAs exhibit alternative splicing that encodes the androgen-binding protein (ABP) [22, 53], which differs from SHBG mRNAs by the presence of an exon I (exon A) that does not influence the post-translational modifications required for SHBG secretion [54]. In humans and rats, ABP is produced in the liver [22], Sertoli and Leydig cells [55], and cardiomyocytes [31, 56]. The physiological role of ABPs in peripheral tissues remains poorly understood; however, studies indicate that ABPs regulate the local bioavailability of androgens [56–58]. SHBG/ABPs are polypeptides of 43–44 kDa [20, 50]. The steroid binding domain is in the N-terminus, whereas the regulatory domains can interact with a plasma membrane receptor for SHBG [9, 29, 38, 59, 60]. The human SHBG is a polypeptide of 373 amino acids that constitute a tandem repeat of laminin G-like (LG) domains [9].

Locally produced SHBG modulates the expression of androgen-responsive genes in prostate tissue [61]. Expression of SHBG protein may enhance or inhibit the uptake of androgens in a cell- and tissue-specific manner [62]. SHBG exerts protective roles against excessive androgen exposition during embryonic and fetal cardiogenesis [63]. Hepatic secretion of SHBG is controlled by circulating sex-steroid levels [64, 65]. Others have argued that higher levels of circulating SHBG are compensated in vivo by hypothalamic-pituitary feedback, resulting in higher total sex-steroid concentrations [66]. This is a controversial point, and there is a continuing debate over whether—and by which mechanisms—circulating SHBG regulates total, free, and/or bioavailable sex-steroid concentrations and their physiological responses. Expression of ABP has been described in the human heart, and it has been suggested that this protein influences the bioavailability of gonadal steroids in the myocardium [31].

Transcriptional regulation of SHBG has been mainly studied in fetal liver and hepatocyte cell lines [67]. SHBG protein expression is controlled by peroxisome proliferator-activated receptor γ (PPARγ), a coactivator for several nuclear transcription factors, including the androgen receptor [68]. PPARs regulate cell metabolism and improve ATP generation [69, 70]. A key metabolic regulator is AMP-activated protein kinase (AMPK), which acts as an energy sensor [71]. AMPK/PPAR interaction is critical to upregulate SHBG expression by controlling hepatocyte nuclear factor-4α (HNF4α) [72]. HNF4α affects the transcription of many genes involved in lipid metabolism, and this fact may contribute to explain the reported correlations between circulating SHBG levels and lipid metabolism, glucose metabolism, and in consequence to cardiovascular risks [73, 74]. The SHBG promoter contains PPAR-response elements (PPAR-RE), which are required for SHBG expression. PPARγ acts as a transcriptional inhibitor of SHBG gene expression in the liver [75]. Some controversial results have been reported since women receiving troglitazone (a pharmacologic PPARγ agonist) showed increased circulating SHBG plasma levels [76], while treatment of HepG2 cells with rosiglitazone reduced the secretion of SHBG [75]. It has been reported that GW9662, a different PPARγ antagonist, increased the synthesis of SHBG in HepG2 liver cells [74]. A potential explanation was that footprinted region 3 (FP3) in the SHBG promoter gene contain binding domains for HNF4α, PPARγ, and RXR retinoic acid receptors [77, 78]. Thus, during normal physiological state, HNF4α may bind with high affinity, whereas PPARγ may act as transcriptional inhibitors during alterations of lipid metabolism [75].

Although these studies may homologate certain in vivo conditions, they do not consider that gene expression of SHBG can also be regulated by testosterone [64, 65]. In this context, transfection of NB16 cells, which do not express sex-steroid receptors, with a plasmid expressing the androgen receptor showed that incubation with SHBG-testosterone or different hormone or carrier concentrations induces the expression of a reporter androgen-responsive gene in a concentration-dependent manner [30]. Therefore, transcriptional regulation of SHBG seems to be regulated by testosterone levels and transactivation mediated by androgen receptors [64, 65].

Adiponectin is a protein produced in the white adipose tissue, negatively related with body mass index (BMI), and their plasma levels are decreased in obese
patients. In a study performed in HepG2 human cells, adiponectin increases the levels of SHBG through activation of AMPK-HNF4α signaling [79]. In obese patients, there is a chronic low-grade inflammatory state with high levels of TNFα and IL-1β. TNF-α levels are negatively related with SHBG expression. In hepatoblastoma human cells, TNFα induces reduction of the levels of SHBG through the activation of NFκB and the inhibition of HNF4α P1 promoter activity by the p65 subunit [80]. In streptozotocin-induced diabetic rats, the plasma levels of adiponectin were decreased and have an increase in TNFα and IL6 levels [81]. Also, they showed that adiponectin receptor 1 was increased in the heart of diabetic rats, but the levels of adiponectin did not change. In line with this, the systemic levels of adiponectin in plasma were not able to induce the signaling by adiponectin receptor 1, showing a decrease of pAMPK and GLUT4 expression in cardiomyocytes [81]. This information can be hypothetically related with SHBG levels in the heart and plasma of obese and diabetic patients because they share the same signaling factors (Figure 1).

In cardiomyocytes, it has been reported that testosterone activates AMPK to modulate energy production through GLUT4-dependent glucose uptake [82]. AMPK interaction is critical for upregulating SHBG expression in HepG2 cells [79]. Furthermore, upstream AMPK regulates the activity of PPAR-alpha [83]. In the nucleus, androgen signaling stimulates PPAR activity and peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) to increase the expression of various nuclear-encoded metabolic genes, including oxidative phosphorylation genes [84, 85]. Since cardiac cells express SHBG and HNF4α gene [86], and testosterone activates the transcriptional machinery to express SHBG protein, including PPAR, AMPK, and HNF4α [31, 32, 87], we hypothesize with the possibility that these pathways may be activated to induce cardiac SHBG expression. Transcriptional regulation of SHBG expression involving the AMPK/PPARs pathway also modulates metabolic networks for fatty acid and glucose metabolism during adaptive cardiomyocyte responses [88]. In addition, the protein deacetylase sirtuin 3 (SIRT3) plays cardinal roles in modulating the metabolic network of fatty acid and glucose metabolism for ATP production [89, 90]. Notably, SIRT3 favorably modifies cellular mechanisms implicated in cardiovascular diseases [91, 92]. SIRT expression is controlled by PGC-1α and AMPK [93, 94] and testosterone activates PGC-1α [95], but it remains unknown whether cardioprotective actions of androgens involve SIRT3 signaling.

4. Effects of SHBG and Testosterone on Cardiac Function: Mechanistic Evidence from Animal and Human Research

Most of the research linking SHBG and androgens has been focused on their circulating levels. If altered levels of circulating SHBG are causally related to high cardiovascular risk, raises the question, what is the potential mechanism?

In humans, plasma SHBG levels are influenced by nutritional state, metabolism, and hormonal factors [9, 58, 96, 97]. Patients with obesity and insulin resistance show reduced circulating SHBG levels [74, 98]. Importantly, circulating SHBG levels are strongly correlated with plasma testosterone concentrations and low testosterone levels are strongly associated with metabolic disorders [99–101]. In addition, decreases in SHBG levels are linked to high cardiovascular risk factors [102]. Although metabolic disorders increase the incidence of cardiovascular disease, it is unclear whether SHBG expression has an impact on SHBG receptor signaling or androgen actions in cardiac cells.

Morbidity and mortality in patients with metabolic and cardiac diseases remain high [11] mainly because of the lack of effective cardioprotective strategies to handle cardiometabolic disorders. A 5-year-long follow-up study indicated that men >65 years of age with elevated SHBG and lower total testosterone were independently associated with an increase of both CVD risk and mortality [19, 103]. Circulating SHBG stands as an available marker for assessment of cardiovascular health, especially in the female population, whereas in men similar effects are less known. Future implications of cardiovascular risk assessment and the importance of plasma SHBG in cardiovascular pathophysiology might be even broader since cardiomyocytes of patients suffering from dilated cardiomyopathy produce cardiac SHBG and appear to be internalized, possibly representing a mechanism for delivering sex hormones to the heart [32]. Thus, an interesting concept is that locally expressed SHBG controls testosterone levels in the myocardium to activate additional androgen signaling pathways. Therefore, abnormal locally produced SHBG function might help explain the adverse cardiac metabolic effects of androgen deficiency.

An interesting study in patients with dilated cardiomyopathy demonstrated that cardiomyocytes express an androgen-binding protein, similar to SHBG, and the subcellular distribution matched with androgen receptor location [31]. Moreover, studies in megalin knock-out mice demonstrate a crucial role for this receptor during cardiac development [104]. Immunohistochemical and 3D reconstruction assays showed that these animals had severe cardiovascular anomalies in structures such as aortic arch, common arterial trunk, coronary arteries, and ventricular septum, as well as a marked thinning of the ventricular myocardium [104]. SHBG has been associated with megalin-induced internalization of the protein into the cells; megalin-deficient mice showed defects resembling androgen deficiency [20, 30]. Although reduced levels of circulating SHBG decrease total testosterone levels, the effect of low testosterone on SHBG expression is not fully understood [105].

Low SHBG levels correlated with measures of heart failure severity and were associated with a higher risk of cardiac death. Interestingly, impaired hepatic SHBG expression impacts testosterone levels, and its deficiency is independently linked to cardiometabolic diseases [106]. In pathological conditions with reduced circulating SHBG levels—such as obesity or insulin resistance—the symptoms of testosterone deficiency in men can be exacerbated [8, 32, 58, 98]. Obesity is considered an independent risk
factor for heart failure [17], and mice fed with high-fat diet (HFD) for 16 weeks developed obesity that adversely affects the function and structure of the heart and induces cardiac dysfunction [107]. Moreover, low concentrations of total testosterone and SHBG were strongly associated with an increased likelihood of having metabolic syndrome, independent of other cardiovascular risk factors [108]. It has been proposed that myocytes may produce and secrete ABP in a paracrine manner perhaps to influence the bioavailability of sex-steroids in the myocardium [31]. Low plasma levels of SHBG are associated with several sex-steroid hormone-dependent diseases [109] and have been reported to be an early indicator of cardiovascular risk in individuals suffering from obesity and metabolic syndrome [110–112]. Experimentally, circulating SHBG suppression causes cardiac disorders, partly by mimicking low testosterone level conditions, whereas physiological levels of SHBG and testosterone show cardioprotective effects [14, 25, 73, 102]. Jänne et al. showed that decreased SHBG levels in the kidney by castration can be restored with a treatment with dihydrotestosterone [113]. This experiment shows us that SHBG concentration can be modulated by testosterone but is not fully understood the dependence of testosterone to the variations of SHBG levels and how we can differentiate the effects in cardiometabolic function. Laurent et al. reported that SHBG-tg male mice that overexpress SHBG exhibit an increase in total testosterone concentration compared with wild-type mice, although free levels of testosterone do not change. This result changed when the mice were castrated, eliminating the hypothalamic feedback of luteinizing hormone over Leydig cells, showing a decrease in free testosterone levels [114]. Furthermore, SHBG-tg mice showed a significant decrease in the weight of the seminal bladder and levator ani/bulbocavernous muscle, organs that are sensitive to androgens [114]. In accordance with that, Rastrelli et al. demonstrated that high SHBG levels are related to lower PSA and hematocrit, markers of androgen deficiency, and increase ANDROTEST scores, an androgen-dependent clinical parameter, demonstrating that high SHBG levels in humans can be associated with hypogonadism [115]. In line with this observation, Nokoff et al. reported that boys with obesity have lower levels of SHBG and total testosterone in comparison with normal weight controls, but free testosterone levels do not change [116]. This type of data gives us information about the dependency of testosterone levels with SHBG variations and presents the metabolic and physiological effects that SHBG levels can induce in the body, independent of free concentration of testosterone, challenging the free hormone hypothesis. With these antecedents, the dependence of SHBG on cardiometabolic effects is incomplete and future research is needed to probe this question. An interesting hypothesis is that testosterone levels regulate cardiac SHBG expression to positively influence cardiometabolic responses (Figure 2).

![Figure 1: Signaling pathways activated by SHBG. The figure illustrates the action mechanism of SHBG as a hormone carrier and SHBG direct actions.](image-url)
Humanized transgenic mice expressing the human SHBG have been used to study the function of this protein. In this in vivo model, SHBG overexpression prevents both the weight increase and fat accumulation induced by high-fat diet. Additionally, SHBG overexpression also abolishes the increase in insulin, leptin, and resistin and protects against high-fat diet-induced obesity [80, 117]. SHBG overexpression does not change food and water intake or intestinal lipid absorption; however, the author did not measure the testosterone levels [117].

On the other hand, elevated levels of circulating SHBG bind more estrogens and may be beneficial by reducing the ability of estrogens to promote breast cancer growth. Also, plasma SHBG levels can directly affect cancer growth [118]. High circulating levels of SHBG have also been associated with better cardiovascular health and metabolic status in postmenopausal women [119, 120]. Therefore, cardiac SHBG expression may be associated with intracardiomyocyte testosterone signaling, allowing cardioprotective effects or, otherwise, producing cardiac dysfunction under metabolic disorder conditions. Thus, expression of cardiac SHBG may restrict the anabolic activity of testosterone on the heart, which impairs cardiac SHBG expression and metabolic adaptations. Then, the relationship between low circulating SHBG and low free testosterone may represent early markers of poor cardiovascular health. Physiological effects of testosterone in cardiac cells includes handling of energy substrates and increased gene expression of key enzymes involved in glucose uptake and glycolysis; and regulation of critical transcription factors related to stimuli that affect cardiomyocyte function.

5. Human Diseases and Medications Related to Circulating SHBG

Various human diseases have been associated with altered circulating levels of SHBG, many of which also are linked with high CVD risk (Table 1). In humans, there is diverse information that reflects the bidirectional nature of the relationship between the SHBG levels and metabolic impairment. Different SHBG-gene polymorphisms have been
related with metabolic effects in case-control studies. Low levels of SHBG were correlated with cardiac risk since HDL
dLevels were lower than the normal threshold in patients
with coronary heart disease, and this correlation might be
affected by SHBG polymorphism [130]. Carriers of the
SHBG polymorphisms rs6257 and rs6259 present a higher
risk of diabetes than carriers of other alleles and present low
levels of SHBG[131]. Metabolic diseases have been related to
abnormal levels of this protein in plasma. SHBG mRNAs in
liver and protein levels in serum were lower when the hepatic
triglyceride concentration was high and decrease with the
increase of body mass index [132].

Metabolic diseases have been related with abnormal
levels of this protein in plasma. In obesity, circulating SHBG
levels are decreased to 50% in obese adult women (non-
menopause) compared with lean control patients [121, 122].
Also, girls and boys with obesity have near 70% of circulating
SHBG compared with nonobese [116]. In patients with
diabetes and metabolic syndrome, plasmatic SHBG levels
also show decreased levels compared with controls
[25, 110, 123]. Laaksonen et al. showed that an entire cohort
of patients without diabetes or metabolic syndrome have
34.5 nmol/l of plasma SHBG; nevertheless, some patients
that develop diabetes or metabolic syndrome present low
levels of SHBG ranging to 26.2 and 28.2 nmol/l, respectively
[25]. On the other hand, malnutrition such as anorexia [128]
and Kwashiorkor patients with protein and energy mal-
nutrition show increased plasma SHBG levels compared
with control normal weight individuals [129]. One example
is a longitudinal cohort of patients in whom SHBG levels
were evaluated in anorexia and after a treatment to gain
weight, showing that the levels of SHBG decrease in the gain
weight therapy [129]. This evidence shows that circulating
SHBG levels have a negative correlation with the develop-
ment of obesity/overweight patients and have a positive
correlation in malnutrition patients; therefore, plasma
SHBG levels are correlating with the nutritional state of
patients.

### Table 1: Pathologies and circulating levels of SHBG.

| Author          | Condition | Sex     | Age (years) | SHBG (nmol/l) | p value | Change     |
|-----------------|-----------|---------|-------------|---------------|---------|------------|
| Kopelman et al. | Lean control | Women | 28          | 60±8          |         |            |
| Nokoff et al.   | Obese     | Women   | 10          | 10            | 18      | Decreased  |
| Cupisti et al.  | BMI < 25 kg/m² | Women | 26.41±6.09  | 53.42±23.1    | <0.0001 | Decreased  |
|                 | BMI > 25 kg/m² | Women | 29.23±7.08  | 30.03±14.52   | <0.0001 | Decreased  |
|                 | Normal     | Women   | 10          | 10            | 18      | Decreased  |
|                 | Normal     | Men     | 12          | 12            | 18      | Decreased  |
|                | Normal     | Men     | 12          | 12            | 18      | Decreased  |

The table shows different diseases and some studies that describe the associated circulating SHBG levels. Gender, mean age (±standard deviation), and p value change between different conditions are also presented.

International Journal of Endocrinology
Circulating SHBG is also correlated with endocrinology diseases such as polycystic ovary syndrome (PCOS) and hypothyroidism. In PCOS, the levels of circulating SHBG are decreased compared with control women in a 25%–45% as compared with normal levels [124, 125], whereas in hypothyroidism, the relation is almost the same [126]. Otherwise, in Klinefelter syndrome patients (XXY), there are increased levels of circulating SHBG [127]. In other endocrine diseases such as hypothryroidism, decreased levels of circulating SHBG have been observed, whereas hyperthyroidism leads to increased plasma SHBG levels. This relation has been explained at the level of the transcription factor HNF4α being increased by hyperthyroidism [133].

Nokoff et al. showed that obese children in early puberty state have a decrease in the circulating SHBG levels and total testosterone and have an increase in estrone metabolites, probably by the aromatization of androgens in adipose tissue that can lead to develop hypogonadotrophic hypogonadism in these boys and affect the reproductuve function in the future [116]. There is incomplete information about the impact of plasmatic SHBG and development of cardiometabolic disease in youth, but the evidence showed a correlation between circulating SHBG, hypogonadism, insulin resistance, cardiac metabolism, and dyslipidemia, which are related with low circulating SHBG levels as a result of altered SHBG hepatic production.

Besides hormones and diseases, some medications and dietary compounds alter SHBG liver production [134, 135]. Antiepileptic drugs such as carbamazepine and phenytoin induce an increase in SHBG circulating levels in men and women [134]. Likewise, thiazolidinediones, and oral contraceptives in women, also increase SHBG plasma levels [136]. To the best of our knowledge, only one prospective study has analyzed the effects of changing circulating SHBG levels on cardiometabolic outcomes. In this prospective study, lifestyle interventions directed to obtain favorable changes in circulating levels of SHBG in men and women could not show to influence the risk of developing type 2 diabetes mellitus in the participants [137].

According to our current understanding, the cardioprotective effects of androgens in men have been poorly studied and the deleterious effects exerted by testosterone appear to be controversial. Recent research indicates that administration of testosterone in physiological doses to individuals with metabolic syndrome improves insulin sensitivity and reduces central obesity [138]. Additionally, development of heart failure in individuals with metabolic syndrome is partially reduced by treatment with testosterone in physiological doses [139, 140]. Likewise, subjects with low plasma testosterone levels develop insulin resistance and diabetes, as well as central obesity and heart failure [99, 100, 141, 142]. Moreover, plasma testosterone levels decline with age, while SHBG levels increase, which in turn leads to progression of testosterone deficiency and age-related cardiovascular pathologies [25, 143].

6. Conclusion and Future Research

Given the important roles of androgens in normal men physiology, abnormal levels must be considered one of the main causes implicated in several disorders and pathological conditions [108, 144–146]. According to a 2017 update demography report from the American Heart Association, almost one in three adult men have some type of cardiovascular disease [147]. In the context of human disease relevance, the international expert consensus panel that convened in 2015 concluded that there is a need for a major research initiative to explore the possible cardioprotective benefits of testosterone therapy, implying that there is sufficient evidence regarding the safety of testosterone therapy in hypogonadal men and that the direction of future research should be set toward defining suitable therapeutic options for cardiovascular disease [148, 149]. Research in the field of androgen signaling will provide a considerable understanding of the physiological and pathological roles of SHBG and sex-steroid hormones. Thus, an appropriate description of testosterone signaling considering circulating and cardiac SHBG expression might help explain both physiological and adverse cardiac metabolic roles of androgens (particularly androgen deficiency). Research directed to elucidate whether plasmatic and cardiac SHBG expression is associated with physiological testosterone levels could represent novel research approaches to study insulin resistance, obesity, diabetes, and heart failure.

Data Availability

The data used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

All the authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Acknowledgments

This work was supported by Fondo Nacional de Ciencia y Tecnología (FONDECYT, grant no. 1151118 to ME; FONDECYT, grant nos. 1190406 to PL, 21180537 to MFT, and Tecnología (FONDECYT, grant no.1151118 to ME; FONDECYT, grant nos. 1190406 to PL, 21180537 to MFT, and 21191304 to DL).%?_he authors also thank CONICYT for their doctoral fellowship.

References

[1] C. S. Hayward, C. M. Webb, and P. Collins, “Effect of sex hormones on cardiac mass,” The Lancet, vol. 357, no. 9265, pp. 1354–1356, 2001.

[2] G. A. Laughlin, L. K. McEvoy, D. von Mühlen et al., “Sex differences in the association of Framingham cardiovascular risk score with cognitive decline in community-dwelling elders without clinical heart disease,” Psychosomatic Medicine, vol. 73, no. 8, pp. 683–689, 2011.

[3] Y. Appelman, B. B. van Rijn, M. E. ten Haaf, E. Boersma, and S. A. E. Peters, “Sex differences in cardiovascular risk factors
and disease prevention,” *Atherosclerosis*, vol. 241, no. 1, pp. 211–218, 2015.

[4] G. A. Laughlin, E. Barrett-Conner, and J. Bergstrom, “Low serum testosterone and mortality in older men,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 93, no. 1, pp. 68–75, 2008.

[5] T. V. Pham, E. A. Sosunov, R. Z. Gaimullin, P. Danilo, and M. R. Rosen, “Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I K-blocking drugs,” *Circulation*, vol. 103, no. 17, pp. 2207–2212, 2001.

[6] P. K. Sütteri, J. T. Murai, W. J. Raymoure, R. W. Kuhn, G. L. Hammond, and J. A. Nisker, “The serum transport of steroid hormones,” *Proceedings of the 1981 Laurentian Hormone Conference*, vol. 38, pp. 457–510, 1982.

[7] A. Elagizi, T. S. Köhler, and C. J. Lavie, “Testosterone and cardiovascular health,” *Mayo Clinic Proceedings*, vol. 93, no. 1, pp. 83–100, 2018.

[8] D. C. Anderson, “Sex-hormone-binding globulin,” *Clinical Endocrinology*, vol. 3, no. 1, pp. 69–96, 1974.

[9] G. V. Avvakumov, A. Cherkasov, Y. A. Muller, and G. L. Hammond, “Structural analyses of sex hormone-binding globulin reveal novel ligands and function,” *Molecular and Cellular Endocrinology*, vol. 316, no. 1, pp. 13–23, 2010.

[10] X. Hu, L. Rui, T. Zhu et al., “Low testosterone level in middle-aged male patients with coronary artery disease,” *European Journal of Internal Medicine*, vol. 22, no. 6, pp. e133–e136, 2011.

[11] S. Mottillo, K. B. Filion, J. Genest et al., “The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis,” *Journal of the American College of Cardiology*, vol. 56, no. 14, pp. 1113–1132, 2010.

[12] C. Selby, “Sex hormone binding globulin: origin, function and clinical significance,” *Annals of Clinical Biochemistry: International Journal of Laboratory Medicine*, vol. 27, no. Pt 6, pp. 532–541, 1990.

[13] I. R. Wallace, M. C. McKinley, P. M. Bell, and S. J. Hunter, “Sex hormone binding globulin and insulin resistance,” *Clinical Endocrinology*, vol. 78, no. 3, pp. 321–329, 2013.

[14] M.-Y. Li, S. Rawal, S. N. Hinkle et al., “Sex hormone-binding globulin, cardiometabolic biomarkers, and gestational diabetes: a longitudinal study and meta-analysis,” *Maternal-Fetal Medicine*, vol. 2, no. 1, pp. 2–9, 2020.

[15] S. C. Kołwicz Jr., S. Purohit, and R. Tian, “Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes,” *Circulation Research*, vol. 113, no. 5, pp. 603–616, 2013.

[16] P. Blomstrand, P. Sjöblom, M. Nilsson et al., “Overweight and obesity impair left ventricular systolic function as measured by left ventricular ejection fraction and global longitudinal strain,” *Cardiovascular Diabetology*, vol. 17, no. 1, p. 113, 2018.

[17] I. Caige, D. Ujvárosy, Z. Szabó et al., “The impact of obesity on the cardiovascular system,” *Journal of Diabetes Research*, vol. 2018, Article ID 3407306., 2018.

[18] B. R. Yeap, R. J. Marriott, L. Antonio et al., “Serum testosterone is inversely and sex hormone-binding globulin is directly associated with all-cause mortality in men,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 106, no. 2, pp. e625–e637, 2021.

[19] P. Gyawali, S. A. Martin, L. K. Heilbronn et al., “Cross-sectional and longitudinal determinants of serum sex hormone binding globulin (SHBG) in a cohort of community-dwelling men,” *PLoS One*, vol. 13, no. 7, Article ID e0200078, 2018.

[20] W. Rosner, D. J. Hryb, S. M. Kahn, A. M. Nakhla, and N. A. Romas, “Interactions of sex hormone-binding globulin with target cells,” *Molecular and Cellular Endocrinology*, vol. 316, no. 1, pp. 79–85, 2010.

[21] R. Pasquale, V. Vicennati, D. Bertazzo et al., “Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status,” *Metabolism*, vol. 46, no. 1, pp. 5–9, 1997.

[22] D. R. Joseph, “Structure, function, and regulation of androgen-binding protein/sex hormone-binding globulin,” *Vitamins & Hormones*, vol. 49, pp. 197–280, 1994.

[23] A. L. Goldman, S. Bhasin, F. C. W. Wu, M. Krishna, A. M. Matsumoto, and R. Jasuja, “A reappraisal of testosterone’s binding in circulation: physiological and clinical implications,” *Endocrine Reviews*, vol. 38, no. 4, pp. 302–324, 2017.

[24] M. S. Khan, D. J. Hryb, G. A. Hashim, N. A. Romas, and W. Rosner, “Delineation and synthesis of the membrane receptor-binding domain of sex hormone-binding globulin,” *Journal of Biological Chemistry*, vol. 265, no. 30, pp. 18362–18365, 1990.

[25] D. E. Laaksonen, L. Niskanen, K. Punnonen et al., “Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men,” *Diabetes Care*, vol. 27, no. 5, pp. 1036–1041, 2004.

[26] E.-J. Hong, B. Sahu, O. A. Jänne, and G. L. Hammond, “Cytoplasmic accumulation of incompletely glycosylated SHBG enhances androgen action in proximal tubule epithelial cells,” *Molecular Endocrinology*, vol. 25, no. 2, pp. 269–281, 2011.

[27] M. J. Vos, G. S. Mijnhout, J. M. M. Rondel, W. Baron, and P. H. P. Groeneveld, “Sex hormone binding globulin deficiency due to a homozygous missense mutation,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 99, no. 9, pp. E1798–E1802, 2014.

[28] R. Frairia, N. Fortunati, F. Fissore et al., “The membrane receptor for sex steroid binding protein is not ubiquitous,” *Journal of Endocrinological Investigation*, vol. 15, no. 8, pp. 617–619, 1992.

[29] O. A. Strel’chyonok, G. V. Avvakumov, and L. I. Survilo, “A recognition system for sex-hormone-binding protein-extradiol complex in human decidual endometrium plasma membranes,” *Biochimica et Biophysica Acta*, vol. 802, no. 3, pp. 459–466, 1984.

[30] A. Hammes, T. K. Andreassen, R. Spoelgen et al., “Role of endocytosis in cellular uptake of sex steroids,” *Cell*, vol. 122, no. 5, pp. 751–762, 2005.

[31] H. Schock, Z. Herbert, H. Sigusch, H. Figulla, G. Jirikowski, and U. Lotze, “Expression of androgen-binding protein (ABP) in human cardiac myocytes,” *Hormone and Metabolic Research*, vol. 38, no. 4, pp. 225–229, 2006.

[32] D. A. Pascual-Figal, P. L. Tornel, F. Nicolás et al., “Sex hormone-binding globulin: a new marker of disease severity and prognosis in men with chronic heart failure,” *Revista Española de Cardiología (English Edition)*, vol. 62, no. 12, pp. 1381–1387, 2009.

[33] H.-O. Jun, D.-h. Kim, S.-W. Lee et al., “Clusterin protects H9c2 cardiomyocytes from oxidative stress-induced apoptosis via Akt/GSK-3β signaling pathway,” *Experimental and Molecular Medicine*, vol. 43, no. 1, pp. 53–61, 2011.
p2oxisome proliferator-activated receptor-alpha and -gamma: implications for PP ARs' roles in renal function,” *Fl oS One*, vol. 6, no. 2, Article ID e16794, 2011.

[35] M. R. Hayden, J. Habibi, A. Whaley-Connell et al., “Nebivol attenuates maladaptive proximal tubule remodeling in transgenic rats,” *American Journal of Nephrology*, vol. 31, no. 3, pp. 262–272, 2010.

[36] R. N. Re and J. L. Cook, “The mitochondrial component of intracrine action,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 299, no. 3, pp. H577–H583, 2010.

[37] Q. Li, F. Lei, Y. Tang et al., “Megalrin mediates plasma membrane to mitochondria cross-talk and regulates mitochondrial metabolism,” *Cellular and Molecular Life Sciences*, vol. 75, no. 21, pp. 4021–4040, 2018.

[38] A. M. Nakhl, “5 alpha-Androstan-3alpha,17beta-diol is a hormone: stimulation of CAMP accumulation in human and dog prostate,” *Journal of Clinical Endocrinology & Metabolism*, vol. 80, no. 7, pp. 2259–2262, 1995.

[39] F. Fissore, N. Fortunati, A. Comba et al., “The receptor-mediated action of sex steroid binding protein (SBP, SHBG): accumulation of cAMP in MCF-7 cells under SBP and estradiol treatment,” *Steroids*, vol. 59, no. 11, pp. 661–667, 1994.

[40] L. A. Fields, A. Koschinski, and M. Zaccolo, “Sustained exposure to catecholamines affects CAM/PKA compartmentalized signalling in adult rat ventricular myocytes,” *Cellular Signalling*, vol. 28, no. 7, pp. 725–732, 2016.

[41] A. Balogh, E. Karpati, A. E. Schneider et al., “Sex hormone-binding globulin provides a novel entry pathway for estradiol and influences subsequent signaling in lymphocytes via membrane receptor,” *Scientific Reports*, vol. 9, no. 1, p. 4, 2019.

[42] L. Yang, S. Xie, M. S. Jamaluddin et al., “Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells,” *Journal of Biological Chemistry*, vol. 280, no. 39, pp. 33558–33565, 2005.

[43] J. Yang and G. D. Holman, “Insulin and contraction stimulate exocytosis, but increased AMP-activated protein kinase activity resulting from oxidative metabolism stress slows endocytosis of GLUT4 in cardiomyocytes,” *Journal of Biological Chemistry*, vol. 280, no. 6, pp. 4070–4078, 2005.

[44] K.-i. Ozaki, M. Awazu, M. Tamiya et al., “Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes,” *American Journal of Physiology-Endocrinology and Metabolism*, vol. 310, no. 8, pp. E643–E651, 2016.

[45] X. Huang, G. Liu, J. Guo, and Z. Su, “The P13K/AKT pathway in obesity and type 2 diabetes,” *International Journal of Biological Sciences*, vol. 14, no. 11, pp. 1483–1496, 2018.

[46] S. Gershagen, A. Lundwall, and P. Fernlund, “Characterization of the human sex hormone binding globulin (SHBG) gene and demonstration of two transcripts in both liver and testis,” *Nucleic Acids Research*, vol. 17, no. 22, pp. 9245–9258, 1989.

[47] G. L. Hammond, “Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins,” *Endocrine Reviews*, vol. 11, no. 1, pp. 65–79, 1990.

[48] U. Westphal, “Steroid-protein interactions revisited,” *Steroid-Protein Interactions II*, vol. 27, pp. 1–7, 1986.

[49] S. Gershagen, A. Doebeli, S. Jeppsson, and G. Rannevik, “Decreasing serum levels of sex hormone-binding globulin around the menopause and temporary relation to changing levels of ovarian steroids, as demonstrated in a longitudinal study,” *Fertility and Sterility*, vol. 51, no. 4, pp. 616–621, 1989.

[50] G. L. Hammond, “Diverse roles for sex hormone-binding globulin in reproduction,” *Biology of Reproduction*, vol. 85, no. 3, pp. 431–441, 2011.

[51] J. Bobe, Y. Guiguen, and A. Fostier, “Diversity and biological significance of sex hormone-binding globulin in fish, an evolutionary perspective,” *Molecular and Cellular Endocrinology*, vol. 316, no. 1, pp. 66–78, 2010.

[52] J. Bobe, S. Mahé, T. Nguyen et al., “A novel, functional, and highly divergent sex hormone-binding globulin that may participate in the local control of ovarian functions in salmonids,” *Endocrinology*, vol. 149, no. 6, pp. 2980–2989, 2008.

[53] D. R. Joseph, “Sequence and functional relationships between androgen-binding protein/sex hormone-binding globulin and its homologs protein S, Gas6, laminin, and agrin,” *Steroids*, vol. 62, no. 8-9, pp. 578–588, 1997.

[54] P. M. Sullivan, Y. M. Wang, and D. R. Joseph, “Identification of an alternate promoter in the rat androgen-binding protein/sex hormone-binding globulin gene that regulates synthesis of a messenger RNA encoding a protein with altered function,” *Molecular Endocrinology*, vol. 7, no. 5, pp. 702–715, 1993.

[55] N. Kühn-Velten, D. Bos, R. Schermer, and W. Staub, “Age-dependence of the rat Leydig cell and sertoli cell function,” *Acta Endocrinologica*, vol. 115, no. 2, pp. 275–281, 1987.

[56] M. Becchi, P. M. Sullivan, P. Ordonneau, P. Petrusz, and D. R. Joseph, “Distribution of immunoreactive androgen-binding protein/sex hormone-binding globulin in tissues of the fetal rat,” *Steroids*, vol. 61, no. 7, pp. 392–400, 1996.

[57] A. Clerico, C. Passino, and M. Emdin, “When gonads talk to the heart,” *Journal of the American College of Cardiology*, vol. 58, no. 6, pp. 627–628, 2011.

[58] E. A. Jankowska and P. Ponikowski, “Sex hormone-binding globulin and heart failure: a passive carrier of steroid hormones or an active hormone itself?” *Revista Española de Cardiología (English Edition)*, vol. 62, no. 12, pp. 1353–1355, 2009.

[59] N. Fortunati, F. Fissore, A. Fazzari, L. Berta, L. Varvello, and R. Faria, “Receptor for sex-steroid-binding protein of endometrium membranes: solubilization, partial characterization, and role of estradiol in steroid-binding protein-soluble receptor interaction,” *Steroids*, vol. 57, no. 9, pp. 464–470, 1992.

[60] N. Fortunati, R. Faria, F. Fissore, L. Berta, A. Fazzari, and G. Gaidano, “The receptor for human sex steroid binding protein (SBP) is expressed on membranes of neoplastic endometrium,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 42, no. 2, pp. 185–191, 1992.

[61] D. J. Hryb, A. M. Nakhl, S. M. Kahn et al., “Sex hormone-binding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector,” *Journal of Biological Chemistry*, vol. 277, no. 29, pp. 26618–26622, 2002.

[62] D. A. Damassa and J. M. Cates, “Sex hormone-binding globulin and heart failure: a passive carrier of steroid hormones or an active hormone itself?” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 316, no. 1, pp. 66–78, 2010.
[65] I. R. Lee, S. A. Dawson, J. D. Wetheralli, and R. Hahnel, “Sex hormone-binding globulin secretion by human hepatocarcinoma cells is increased by both estrogens and androgens,” The Journal of Clinical Endocrinology & Metabolism, vol. 64, no. 4, pp. 825–831, 1987.

[66] M. R. Laurent, C. Helsen, L. Antonio et al., “Effects of sex hormone-binding globulin (SHBG) on androgen bioactivity in vitro,” Molecular and Cellular Endocrinology, vol. 437, pp. 280–291, 2016.

[67] P. M. Sullivan, P. Petrusz, C. Szpirer, and D. R. Joseph, “Alternative processing of androgen-binding protein RNA transcripts in fetal rat liver. Identification of a transcript formed by trans splicing,” Journal of Biological Chemistry, vol. 266, no. 1, pp. 143–154, 1991.

[68] G. E. Muscat and U. Dressel, “Cardiovascular disease and PPARdelta: targeting the risk factors,” Current Opinion in Investigational Drugs (London, England: 2000), vol. 6, no. 9, pp. 887–894, 2005.

[69] P. M. Barger and D. P. Kelly, “PPAR signaling in the control of cardiac energy metabolism,” Trends in Cardiovascular Medicine, vol. 10, no. 6, pp. 238–245, 2000.

[70] B. Finck, “The PPAR regulatory system in cardiomyogenesis and disease,” Cardiovascular Research, vol. 73, no. 2, pp. 269–277, 2007.

[71] C. Cantó, Z. Gerhart-Hines, J. N. Feige et al., “AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity,” Nature, vol. 458, no. 7241, pp. 1056–1060, 2009.

[72] G. B. Rha, G. Wu, S. E. Shoelson, and Y.-I. Chi, “Multiple binding modes between HNF4α and the LXXLL motifs of PGC-1α lead to full activation,” Journal of Biological Chemistry, vol. 284, no. 50, pp. 35165–35176, 2009.

[73] M. Pugeat, P. Moulin, P. Cousin et al., “Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 53, no. 1–6, pp. 567–572, 1995.

[74] M. Pugeat, N. Nader, K. Hogevseen, G. Raverot, H. Déchaud, and C. Grenot, “Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome,” Molecular and Cellular Endocrinology, vol. 316, no. 1, pp. 53–59, 2010.

[75] D. M. Selva and G. L. Hammond, “Peroxisome-proliferator receptor γ represses hepatic sex hormone-binding globulin expression,” Endocrinology, vol. 150, no. 5, pp. 2183–2189, 2009.

[76] R. Azziz, “Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial,” Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 4, pp. 1626–1632, 2001.

[77] M. Jánne and G. L. Hammond, “Hepatocyte nuclear factor-4 controls transcription from a TATA-less human sex hormone-binding globulin gene promoter,” Journal of Biological Chemistry, vol. 273, no. 51, pp. 34105–34114, 1998.

[78] C. N. A. Palmer, M.-H. Hsu, K. J. Griffin, and E. F. Johnson, “Novel sequence determinants in peroxisome proliferator signaling,” Journal of Biological Chemistry, vol. 270, no. 27, pp. 16114–16121, 1995.

[79] R. Simó, C. Saez-Lopez, A. Lecube, C. Hernandez, J. M. Fort, and D. M. Selva, “Adiponectin upregulates SHBG production: molecular mechanisms and potential implications,” Endocrinology, vol. 155, no. 8, pp. 2820–2830, 2014.

[80] C. Saéz-López, M. Rivera-Giménez, C. Hernández, R. Simó, and D. M. Selva, “SHBG-C57BLKSj-db/db: a new mouse model to study SHBG expression and regulation during obesity development,” Endocrinology, vol. 156, no. 12, pp. 4571–4581, 2015.

[81] Z. Guo, Z. Xia, V. G. Yuen, and J. H. McNeill, “Cardiac expression of adiponectin and its receptors in streptozotocin-induced diabetic rats,” Metabolism, vol. 56, no. 10, pp. 1363–1371, 2007.

[82] C. Wilson, “Testosterone increases GLUT4-dependent glucose uptake in cardiomyocytes,” Journal of Cellular Physiology, vol. 228, no. 12, pp. 2399–2407, 2013.

[83] R. Meng, “AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway,” Archives of Biochemistry and Biophysics, vol. 511, no. 1–2, pp. 1–7, 2011.

[84] J. G. Duncan and B. N. Finck, “The PPARα/PGC-1α axis controls cardiac energy metabolism in healthy and diseased myocardium,” PPAR Research, vol. 2008, Article ID 253817, 10 pages, 2008.

[85] W. Fan and R. Evans, “PPARs and ERRs: molecular mediators of mitochondrial metabolism,” Current Opinion in Cell Biology, vol. 33, pp. 49–54, 2015.

[86] A. P. Harris, K. A. Ismail, M. Nunez et al., “Trichloroethylene perturbs HNF4a expression and activity in the developing chick heart,” Toxicology Letters, vol. 285, pp. 113–120, 2018.

[87] M. E. Pepin, C. Koentges, K. Pfeifer et al., “Dysregulation of the mitochondrial proteome occurs in mice lacking adiponectin receptor 1,” Frontiers in Endocrinology, vol. 10, p. 872, 2019.

[88] L. Nascimben, J. S. Ingwall, B. H. Lorell et al., “Mechanisms for increased glycolysis in the hypertrophied rat heart,” Hypertension, vol. 44, no. 5, pp. 662–667, 2004.

[89] M. N. Sack, “Emerging characterization of the role of SIRT3-mediated mitochondrial protein deacetylation in the heart,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 301, no. 6, pp. H2191–H2197, 2011.

[90] M. N. Sack, “The role of SIRT3 in mitochondrial homeostasis and cardiac adaptation to hypertrophy and aging,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 3, pp. 520–525, 2012.

[91] S. Javadov and N. Escobales, “The role of SIRT3 in mediating cardioprotective effects of RAS inhibition on cardiac ischamia-reperfusion,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 18, no. 3, pp. 547–550, 2015.

[92] Y. Lu, Y.-d. Wang, X.-y. Wang, H. Chen, Z.-j. Cai, and M.-x. Xiang, “SIRT3 in cardiovascular diseases: emerging roles and therapeutic implications,” International Journal of Cardiology, vol. 220, pp. 700–705, 2016.

[93] A. Giralt, E. Hondares, J. A. Villena et al., “Peroxisome proliferator-activated receptor-γ coactivator-1α controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype,” Journal of Biological Chemistry, vol. 286, no. 19, pp. 16958–16966, 2011.

[94] I. Ircher, V. Ljubicic, A. F. Kirwan, and D. A. Hood, “AMP-activated protein kinase-regulated activation of the PGC-1α promoter in skeletal muscle cells,” PLoS One, vol. 3, no. 10, e3614, 2008.

[95] J. B. Tennakoon, Y. Shi, J. J. Han et al., “Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch,” Oncogene, vol. 33, no. 45, pp. 5251–5261, 2014.

[96] A. L. Eriksson, M. Lorentzon, D. Mellström et al., “SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolism levels, and hip bone mineral density,” The
[124] P. Ferk, N. Teran, and K. Gersak, “The (TAAAA)n microsatellite polymorphism in the SHBG gene influences serum SHBG levels in women with polycystic ovary syndrome,” Human Reproduction, vol. 22, no. 4, pp. 1031–1036, 2007.

[125] D. P. Baldani, L. Skrgatic, J. Z. Cerne, S. K. Oguc, B. M. Gersak, and K. Gersak, “Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome,” Molecular Medicine Reports, vol. 11, no. 5, pp. 3941–3947, 2015.

[126] J. Leger, M. G. Forest, and P. Czernichow, “Thyroid hormones influences sex steroid binding protein levels in infancy: study in congenital hypothyroidism,” The Journal of Clinical Endocrinology & Metabolism, vol. 71, no. 5, pp. 1147–1150, 1990.

[127] S. R. Plymate, J. M. Leonard, C. A. Paulsen, B. L. Fariss, and A. E. Karpas, “Sex hormone-binding globulin changes with androgen replacement,” The Journal of Clinical Endocrinology & Metabolism, vol. 57, no. 3, pp. 645–648, 1983.

[128] B. Estour, M. Pugeat, F. Lang, H. Dechaud, J. Pellet, and H. Yilmaz-Aydogan, “Genetic polymorphisms of the SHBG gene can be the effect on SHBG and HDL-cholesterol levels in coronary heart disease: a case-control study,” Molecular Biology Reports, vol. 46, no. 4, pp. 4259–4269, 2019.

[129] N. Pascal, E. K. S. Amouzou, A. Sanni et al., “Serum concentrations of sex hormone binding globulin are elevated in kwashiorkor and anorexia nervosa but not in marasmus,” The American Journal of Clinical Nutrition, vol. 76, no. 1, pp. 239–244, 2002.

[130] O. Kurnaz-Gomleksiz, B. Akadam-Teker, Z. Bugra, B. Omer, and H. Yilmaz-Aydogan, “Genetic polymorphisms of the SHBG gene can be the effect on SHBG and HDL-cholesterol levels in coronary heart disease: a case-control study,” Molecular Biology Reports, vol. 46, no. 4, pp. 4259–4269, 2019.

[131] S. A. El Tarhouny, “Study of sex hormone-binding globulin gene polymorphism and risk of type 2 diabetes mellitus in Egyptian men,” The West Indian Medical Journal, vol. 64, no. 4, pp. 338–343, 2015.

[132] S. J. Winters, J. Gogineni, M. Karegar et al., “Sex hormone-binding globulin gene expression and insulin resistance,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 12, pp. E2780–E2788, 2014.

[133] D. M. Selva and G. L. Hammond, “Thyroid hormones act indirectly to increase sex hormone-binding globulin production by liver via hepatocyte nuclear factor-4α,” Journal of Molecular Endocrinology, vol. 43, no. 1, pp. 19–27, 2009.

[134] S. Svalheim, L. Sveberg, M. Mochoł, and E. Taubøll, “Interactions between antiepileptic drugs and hormones,” Seizure, vol. 28, pp. 12–17, 2015.

[135] R. Simó, C. Sáez-López, A. Barbosa-Desongles, C. Hernández, and D. M. Selva, “Novel insights in SHBG regulation and clinical implications,” Trends in Endocrinology & Metabolism, vol. 26, no. 7, pp. 376–383, 2015.

[136] G. L. Hammond, “Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action,” Journal of Endocrinology, vol. 230, no. 1, pp. R13–R25, 2016.

[137] V. R. Aroda, C. A. Christophi, S. L. Edelstein et al., “Cirulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program,” BMJ Open Diabetes Research & Care, vol. 8, no. 2, 2020.

[138] F. Saad, A. Aversa, A. Isidori, and L. Gooren, “Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review,” Current Diabetes Reviews, vol. 8, no. 2, pp. 131–143, 2012.

[139] C. J. Malkin, T. H. Jones, and K. S. Channer, “The effect of testosterone on insulin sensitivity in men with heart failure,” European Journal of Heart Failure, vol. 9, no. 1, pp. 44–50, 2007.

[140] C. J. Malkin, P. J. Pugh, J. N. West, E. J. R. van Beek, T. H. Jones, and K. S. Channer, “Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial,” European Heart Journal, vol. 27, no. 1, pp. 57–64, 2006.

[141] A. Chandel, S. Dhindsa, S. Topiwala, A. Chaudhuri, and P. Dandona, “Testosterone concentration in young patients with diabetes,” Diabetes Care, vol. 31, no. 10, pp. 2013–2017, 2008.

[142] G. Hackett, M. Kirby, and A. I. Sinclair, “Testosterone deficiency, cardiac health, and older men,” International Journal of Endocrinology, vol. 2014, p. 134763, 2014.

[143] J. S. Brand, Y. T. van der Schouw, M. Dowsett et al., “Testosterone, SHBG and differential white blood cell count in middle-aged and older men,” Maturitas, vol. 71, no. 3, pp. 274–278, 2012.

[144] B. Lunenfeld, “Testosterone deficiency and the metabolic syndrome,” The Aging Male, vol. 10, no. 2, pp. 53–56, 2007.

[145] P. Dandona and S. Dhindsa, “Update: hypogonadotrophic hypogonadism in type 2 diabetes and obesity,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 9, pp. 2643–2651, 2011.

[146] T. Muthusamy, S. Dhevika, P. Murugesan, and K. Balasubramanian, “Testosterone deficiency impairs glucose oxidation through defective insulin and its receptor gene expression in target tissues of adult male rats,” Life Sciences, vol. 81, no. 7, pp. 534–542, 2007.

[147] A. H. A. H. D. a. S. Statistics, “Heart disease and stroke statistics—2017 update: a report from the American heart association,” Circulation, vol. 136, no. 10, 2017.

[148] I. Baillargeon, R. J. Urban, Y.-F. Kuo et al., “Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001–2010,” Public Health Reports, vol. 130, no. 2, pp. 143–152, 2015.

[149] A. Morgenstaler, M. Zitzmann, A. M. Traish, and A. Fox, “International expert consensus conference on testosterone deficiency and its treatment held in Prague, Czech Republic,” The Aging Male, vol. 18, no. 4, pp. 205–206, 2015.